Navinta Infringed Abraxis' Naropin Patents: Judge

Law360, New York (August 4, 2009, 5:43 PM EDT) -- Generic-drug manufacturer Navinta LLC has been found liable for infringing three patents for Abraxis BioScience Inc.'s injectable pain management drug Naropin.

Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey issued the finding Monday, two days before the 30-month stay on regulatory approval for Navinta's proposed generic was set to expire.

Judge Pisano conducted a bench trial from July 20 to 28 to decide whether the proposed generic described in Navinta's 2006 abbreviated new drug application with the U.S. Food...
To view the full article, register now.